Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Mymetics Corp (MYMX)

Mymetics Corp (MYMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant AccessWire - Wed Nov 18, 2020

- Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. - Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern...

MYMX : 0.0100 (-96.16%)
Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine AccessWire - Mon Nov 2, 2020

- Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based...

MYMX : 0.0100 (-96.16%)
Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine AccessWire - Wed Sep 23, 2020

- Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective...

MYMX : 0.0100 (-96.16%)
Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2) AccessWire - Thu Jun 11, 2020

EPALINGES, SWITZERLAND / ACCESSWIRE / June 11, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life...

MYMX : 0.0100 (-96.16%)
Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy AccessWire - Thu May 28, 2020

EPALINGES, SWITZERLAND / ACCESSWIRE / May 28, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life...

MYMX : 0.0100 (-96.16%)

Barchart Exclusives

My Annual Public Service Announcement regarding NASS' Weekly Reports Barchart - 37 minutes ago
I know there are new readers to this site every year. Given that, I feel compelled to post my annual Public Service Announcement regarding NASS' weekly numbers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot